National Research Council, Italy Report issue

Government Phase 3

Organization Overview

First Clinical Trial
2011
NCT01680198
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Institute of Biomedical Technologies-National Research Council, Italy

Active Ingredients

Drugs in Phase 3 Trials (1)

paricalcitol (zemplar) (1 trial)

Drugs in Other Trials (2)

fiber (1 trial)

prebiotic fiber (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Kidney Diseases (Phase 3)

Renal Insufficiency, Chronic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3